Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Point mutations in isocitrate dehydrogenase I (IDH1) and IDH2 are found in majority of grade II and III gliomas. R132H is the most common IDH1 substitution found in gliomas.
BT142 mut/- contains a homozygous IDH1 R132H mutation, which originated from a heterozygous IDH1 R132H BT142 cells.
The cells grow as phase-bright, smooth spheres.
The neurospheres should not get too big, ragged or dark as this is a sign of unhealthy, dying cells.
The cells should be passaged when the neurospheres are 200 to 400 µm in size.
The cells grow as phase-bright, smooth spheres. The neurospheres should not get too big, ragged or dark as this is a sign of unhealthy, dying cells. The cells should be passaged when the neurospheres are about 200-400 μm in size.
Volumes used in this protocol are for 75 cm2 flask.
Note: If accurate cell count is necessary, Accumax (Catalog No. AM105, Innovative Cell Technologies) can be used; however, the cells may take some time to recover from an enzymatic dissociation.
Luchman HA et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol. 14:184-191, 2012. PubMed: 22166263
